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Abstract 
Study Design. Analysis of a prospective, multicenter cohort study. 
Objective. The aim of our study was to compare thresholds of published minimal clinically 
important differences (MCID) for the 3-level EuroQol-5D health survey (EQ-5D-3L) summary 
index (range -0.53 to 1.00) with our anchor-based estimate and evaluate how useful these 
thresholds are in determining treatment success in patients undergoing surgery for degenerative 
lumbar spinal stenosis (DLSS).  
Summary of Background Data. MCID values for EQ-5D-3L are specific to the underlying 
disease and only three studies have been published for DLSS patients reporting different values. 
Methods. Patients of the multi-center Lumbar Stenosis Outcome Study (LSOS) with confirmed 
DLSS undergoing first-time decompression or fusion surgery with 12-month follow-up were 
enrolled in this study. To calculate MCID we used the Spinal Stenosis Measure (SSM) 
satisfaction subscale as anchor. 
Results. For this study, 364 patients met the inclusion criteria; of these, 196 were very satisfied, 
72 moderately satisfied, 43 somewhat satisfied and 53 unsatisfied 12-month after surgery. The 
MCID calculation estimated for EQ-5D-3L a value of 0.19. Compared to published MCID 
values (ranging from 0.30 to 0.52), our estimation is less restrictive. 
Conclusions. In patients with LSS undergoing surgery, we estimated an MCID value for EQ-
5D-3L summary index of 0.19 with help of the average change anchor-based method, which we 
find to be the most suitable method for assessing patient change scores. 
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Key Points 
 Minimal clinically important differences (MCID) values for EQ-5D-3L are specific to the 
underlying disease and a useful concept to assess treatment success. 
 Only three studies have been published yet calculating MCID of EQ-5D-3L summary 
index for patients with degenerative lumbar spinal stenosis undergoing surgery reporting 
different values. 
 We estimated an MCID value of 0.19 based on the average change anchor method, which 
we find to be the most suitable method for assessing patient change scores. 
 Compared to previously published MCID values (ranging from 0.30 to 0.52), our 
estimation is less restrictive. 
 
Key Words: clinical meaningful improvement; decompression; degenerative lumbar spinal 
stenosis; EQ-5D; Fusion; meaningful clinical improvement; MCID; multi-center; quality of life; 
spine-surgery 
Level of Evidence: 3 
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Introduction 
Degenerative lumbar spinal stenosis (DLSS) is a highly prevalent condition and causes 
considerable pain and disability.
1
 It has a remarkable impact on the patient’s daily life and 
health. The treatment options range from conservative (pain management, physiotherapy, 
epidural steroid injections) to surgical approaches. Further, DLSS is the most frequent 
indication for spine surgery in patients older than 65 years of age.
2
 Nevertheless, the amount 
of benefit of the surgery varies and one third of the patients did not report an improvement in 
pain, disability, or quality of life after surgery.
3-6
 However, less is known about the surgery’s 
impact on quality of life. 
The EuroQol five-dimensional questionnaire (EQ-5D) is a standardized instrument to 
measure health-related quality of life (HRQOL).
7
 The EQ-5D is a short self-administered 
patient-reported outcome measure (PROM) broadly applied in clinical studies to capture the 
health status from the patients’ perspective.  
To facilitate the interpretation of the evaluation of PROMs and hence the clinical relevance 
of a treatment effect, the “minimal clinically important difference” (MCID) is a useful 
concept.
8
 It was proposed by Jaeschke et al.
9
 in 1989 and it is defined as “the smallest 
difference in a score that is considered to be worthwhile or important”.10 Thus, the MCID 
determines a threshold for a clinically relevant change in a PROM − in contrast to the “mere” 
statistical significance threshold that does not automatically mean a clinically relevant benefit 
from therapy. If an average patient reaches or even exceeds the aforementioned MCID 
threshold, they consider their change as worthwhile and meaningful.
11
 
MCID values are specific to the underlying disease
12,13
 and have been already estimated for 
the 3-level version of EQ-5D (EQ-5D-3L) for various spinal disorders.
14-16
 For patients with 
DLSS, we identified three studies that calculated an MCID, however, the values proposed 
varied considerably between 0.30 and 0.52 using the anchor-based mean change approach.
17-19
 
Considering an EQ-5D-3L score range of -0.53 to 1.00, an MCID of 0.52 would require an 
enormous change, which could hardly be classified as minimal. Further, all three studies were 
performed in the USA and consequently used another value set for the analysis due to 
different population norms. Hence, studies conducted in Europe may find the proposed 
MCIDs unsuitable.  
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The aim of our study is to compare these thresholds with our own anchor-based estimate 
and evaluate how useful these thresholds are in determining treatment success in patients 
undergoing surgery included in the Lumbar Stenosis Outcome Study (LSOS) performed in 
Switzerland. 
 
Methods 
Study design 
For this retrospective analysis, we used data from the Lumbar Stenosis Outcome Study (LSOS). 
The LSOS is conducted as a prospective cohort study in the Rheumatology and Spine Surgery 
Units at eight medical centers (which service a region in Switzerland with approximately two 
million inhabitants). They were eligible for the LSOS study if they 1) were aged 50 years or 
more, 2) had a history of neurogenic claudication, 3) had lumbar spinal stenosis verified by 
Magnetic Resonance Imaging (MRI) or Computer Tomography (CT), 4) had no evidence of 
stenosis caused by tumor, infection, fracture, or significant deformity (>15° lumbar scoliosis, 
diagnosed on conventional x-ray with anterior-posterior and lateral views), and 5) had no clinical 
peripheral artery occlusive disease. The decision of the treatment strategy (conservative or 
surgical) was made by the patient and his attending physician. Additional information about 
LSOS is available elsewhere.
20
  
 
Eligibility criteria for being included in this analysis 
All patients were eligible who: met the above mentioned inclusion criteria, underwent first-time 
decompression surgery alone or additional fusion surgery within the first six months of 
enrollment, and had a 12-month follow-up.  
Patients who had previous lumbar spine surgery, whose lumbar spine surgery was later than 6 
months after study enrolment, who underwent revision surgery, or who received only 
conservative care and/or epidural injection were excluded. 
 
Outcome Measures 
EQ-5D: The EuroQol five-dimensional self-administered questionnaire (EQ-5D) is a 
standardized instrument to measure health-related quality of life and was developed by the 
EuroQol Group.
7
 The EQ-5D descriptive system measures the health state in five dimensions 
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(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), either with three 
levels of severity for each dimension (EQ-5D-3L), the most widely used version,
21
 or with five 
levels (EQ-5D-5L).
7
 The five dimensions can be reported as a single 5-digit number (from 11111 
representing full health to 33333 [for EQ-5D-3L] or 55555 [for EQ-5D-5L], respectively, 
meaning worst health). With help of a value set (depending on population norms), the health 
state can be converted into a single summary index value. This value can range from -0.53 (for 
the French population) to 1, with 0 representing a health state equivalent to being dead and 1 
indicating full health. The French value set was used to the calculation of summary index, as 
there is no Switzerland specific value set.
22
 Further, the LSOS study only applied the EQ-5D-3L 
questionnaire.  
The EQ-5D-3L was found to be an effective measure of health status in patients with 
degenerative lumbar spine pathologies (conservatively or surgically treated).
23
 Further, its 
reliability was evaluated in patients undergoing low-back surgery and was determined to be 
“solid” (intraclass correlation coefficient (ICC) varied between 0.82 (95% confidence interval 
(CI) 0.67 to 0.90, p<0.001) and 0.87 (95% CI 0.72 to 0.94, p<0.001)).
24
 
Spinal Stenosis Measure (SSM): The SSM, also known as Zurich Claudication Questionnaire 
(ZCQ), is a self-administered validated three-part questionnaire that was specifically designed 
for DLSS patients to measure their severity of symptoms and disability.
25
 It is widely used in 
studies on DLSS
26-29
 and recommended by the North American Spine Society (NASS). It 
consists of three different subscales; the symptom severity subscale, the physical function 
subscale and the satisfaction subscale. The subscale score ranges are 1−5, 1−4 and 1−4 (best-
worst). The corresponding ICC values were 0.87 (95% CI 0.81 to 0.92), 0.81 (95% CI 0.71 to 
0.87), and 0.90 (95% CI 0.84 to 0.93), respectively.
30
 MCID in SSM symptoms is defined as an 
improvement (decrease) by at least 0.48 points, in SSM function by at least 0.52 points.
31
 
 
Anchor Measures 
SSM satisfaction subscale was used as anchor. This is a set of six questions asked following 
treatment to evaluate a patient’s satisfaction with their treatment. The six questions have possible 
responses 1 (very satisfied), 2 (somewhat satisfied), 3 (somewhat dissatisfied), and 4 (very 
dissatisfied) which are averaged to give an overall satisfaction score. A score more than 2.5 
represents a patient who is on average unsatisfied with the treatment. Stucki et al.
25
 further 
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divided the range of satisfied scores into “very”, “moderately”, and “somewhat”. Using this 
classification system, we use the patients who were somewhat satisfied to represent a minimal 
improvement like in previous studies.
25,31
 The cut-offs for the somewhat group are less than or 
equal to 2.5 and greater than 2.0. 
The other subscales of the SSM questionnaire (symptoms and function) were used as 
reference to validate the selected MCID. 
 
Selection of MCID 
We used the “mean change” method to calculate the MCID.9 This identifies the average change 
from baseline to follow-up in the outcome of interest (EQ-5D-3L) in those patients with the 
smallest positive response in the anchor (SSM Satisfaction). 
To show the influence of the different population normed value sets on the calculation of the 
summary index for the EQ-5D-3L and hence of the MCID, we additionally applied the value sets 
of the UK, US, and German population in our patient sample. 
 
Statistical analysis 
We summarized the patient characteristics at baseline with means and standard deviations (SD) 
and counts and percentages as appropriate. To test for differences between the groups of patients 
with different satisfaction levels we used Chi-squared tests for categorical variables and Welch’s 
two-sided t-tests for continuous variables and reported p-values. As this was descriptive only, we 
did not set a threshold on the p-values. 
We showed the relationship between SSM Satisfaction and change in EQ-5D-3L with a 
scatter plot and linear slopes and calculated the Pearson correlation coefficient. 
To compare how the threshold derived in LSOS differs from the previously published 
thresholds, we compared the number and percentage of patients reaching MCID using each 
threshold and depicted this graphically.  
All analyses were conducted with R for Windows.
32
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Results 
Patient characteristics at baseline 
Between December 2010 and December 2015, 841 patients agreed to participate in the LSOS 
study (Figure 1). For this analysis, 364 patients met the inclusion criteria; of these, 196 were 
very satisfied, 72 moderately satisfied, 43 somewhat satisfied and 53 unsatisfied after 12-month 
follow-up. 
Table 1 presents the baseline characteristics of the somewhat satisfied and unsatisfied patients 
(see also Appendix Table 1  http://links.lww.com/BRS/B563 for the baseline characteristics of 
all 364 patients). Mean age of patients in those both groups were 74 years, 60% were female, and 
76% had symptoms longer than six months. In both groups, around 65% had a spondylolisthesis 
on the level of surgery. Mean baseline EQ-5D-3L summary index values were 0.40 (SD 0.30) for 
all patients, 0.45 (SD 0.28) in the somewhat satisfied group, and 0.35 (SD 0.31) in the unsatisfied 
group. None of the p-values are large and therefore do not suggest a difference between the 
groups. 
 
Estimation of MCID 
The mean change (improvement) in EQ-5D-3L summary index after 12-month follow-up was 
0.19 for the somewhat satisfied, which corresponds to our MCID value, and 0.09 for the 
unsatisfied patients. Figure 2 depicts a positive, albeit weak, relationship between mean SSM 
satisfaction and mean change in EQ-5D-3L summary index between 12-month follow-up and 
baseline in the unsatisfied group: as patient satisfaction improved (i.e. became less unsatisfied) 
changes in EQ-5D-3L became more positive. In the somewhat satisfied group, there was no 
evidence for a positive or negative relationship. 
We fit the linear slopes and correlations separately for the unsatisfied and somewhat satisfied 
patients as we did not wish to assume a linear relationship between EQ-5D and SSM satisfaction 
over the qualitative shift from unsatisfied to satisfied.  
 
Comparison with MCID of SSM symptoms and function 
Figure 3 compares the change of SSM symptoms or function with the change of EQ-5D-3L 
between 12-month follow-up and baseline for all 364 patients. It shows that most patients who 
reached MCID in SSM symptoms or function (solid vertical line) are experiencing an improved 
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
quality of life (66.6% and 74.6%, respectively) when applying our MCID value (solid horizontal 
line). The MCID values of Asher 2018
19
/Parker 2011
17
 (dashed horizontal line) and Parker 
2012
18
 (dotted horizontal line) were more conservative (52.3% and 28.4% for SSM symptoms 
and 59.1% and 34.3% for SSM function, respectively) compared to our MCID value. The 
absolute percentage values for each quadrant can be found in Appendix Table 2  
http://links.lww.com/BRS/B563. 
 
Ceiling effect 
In our patient sample, there are many patients who reached the upper limit of the EQ-5D-3L 
instrument (1.00, best life quality) at 12-month follow-up, in particular in the highly satisfied 
group (53.1%). In the somewhat satisfied group only one patient (2.3%) has a summary index 
value of 1.00 at 12-month follow-up and no patient in the unsatisfied group. Therefore, the 
MCID estimate was not biased by a ceiling effect. 
 
Comparison with other population value sets 
When applying the value set for different populations, we estimated the following MCIDs for 
our patient sample (Appendix Table 3 http://links.lww.com/BRS/B563): for the UK population 
0.22, for the US population 0.14, and for the German population 0.20. The mean change 
(improvement) in EQ-5D-3L between baseline and follow-up was 0.19, 0.13, and 0.19, 
respectively. 
 
Discussion 
In our study investigating patients with lumbar spinal stenosis undergoing surgery, we have 
defined an MCID threshold of 0.19 which shows good agreement with other patient reported 
outcomes (SSM symptoms and function). 
Unlike other studies,
17-19
 we have only used an anchor-based method, as only anchor based 
methods can properly take into account the clinical aspect in to their estimates.
33
 Specifically, we 
use the “average change” method based on the “somewhat satisfied” group.9 Considering the 
definition of MCID (“the smallest difference in a score that is considered to be worthwhile or 
important”),10 we need to differentiate between the before-after difference due to a therapy, and a 
difference between the health status of two groups patients. The “change difference” MCID 
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method is often attributed to Redelmeier et al.
34
 but that publication describes a method for 
comparing patients at a single time point. Today, the “change difference” MCID refers to the 
difference between the change scores of the “slightly improved” patients and the changes scores 
of the “unchanged” patients, i.e. the difference of differences. This “change difference” MCID is 
therefore not suitable for classifying an individual patient’s change score as meaningful or not. 
To see this, consider a study where the “slightly improved” group has an average change score of 
0.19 and the “unchanged” group has an average change of 0.10. The “change difference” MCID 
estimate would be 0.19-0.10=0.09. Therefore, a patient with a score of 0.095 who rated 
themselves as having “no change” would be classified as having a meaningful change because 
they reached MCID (0.095>0.09)! The “change difference” MCID is more suitable for 
classifying the size of a treatment effect. The ROC method is also anchor-based but can be very 
sensitive to the patient sample used and estimates an optimal classification threshold, which does 
not necessarily correspond to the concept of MCID.
35
 Estimates from distribution-based 
methods, such as estimate minimal detectable changes (MCD), half-SD, Cohen’s effect size, etc., 
are statistical in nature and while may be useful in further calculations, are not calculated with 
any reference to clinical importance and so cannot be used by themselves as an MCID. 
Further, we see in our study that the anchor and the measure are not fully in agreement. There 
are patients who report satisfaction but have a negative change in the measure. This may be due 
to nuances in the different questionnaires exposing different aspects of patients’ quality of life. 
Alternatively, it may be due to a response shift phenomena where patients have a different 
conception of their condition after an intervention.
36
 
Some aspects could have led to the differences in MCID values of the studies by Parker et 
al.
17,18
 and Asher et al.
19
 compared to our estimation; first, they included all “satisfied” patients 
whereas we only included “somewhat” satisfied patients. The minimal difference can only be 
estimated with patients in the somewhat group, otherwise the MCID is grossly overestimated,
37
 
and is rather the Average Clinically Important Difference. Further, different anchors (Parker 
2011 and 2012: health transition item (HTI) of the SF-36; Asher 2018: NASS satisfaction scale) 
were used what might have also influenced the MCID values. Second, mean age was much lower 
in their studies than in our patient sample (50.9±11.8, 56.3±12.5 [Parker 2011 and 2012] and 
62.0±11.2 [Asher 2018] vs 74.0±8.1 years in our study). It is well known that age influences 
recovery also in long-term follow-up.
38-40
 All in all, these reasons could have led to greater mean 
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change in EQ-5D between baseline and follow-up (0.43, 0.41 [Parker 2011 and 2012] and 0.24 
[Asher 2018] vs 0.13 in our study) and therefore to higher MCID values. The surgical procedure, 
decompression or fusion surgery, should not have affected the results, as Asher et al.
19
 showed in 
their subgroup analysis separately for laminectomy and fusion patients. They concluded that 
MCID values are rather more specific to the diagnosis than to the procedure type. Therefore, we 
also included decompression as well as fusion procedures in our analysis. 
The studies by Parker et al.
17,18
 and Asher et al.
19
 were all performed in the USA and therefore 
used another population value set. We were able to show that when using the US population 
value set it led to differences up to almost 50% in the estimation of the MCID, compared to using 
European population value sets. Consequently, it is important that the most appropriate 
population value set is used for calculations and for the evaluation of patient outcomes. 
The EQ-5D-3L has some disadvantages regarding its instrument’s sensitivity and the risk of 
encountering ceiling effects. This risk is defined as “the proportion of respondents scoring no 
problems on any of the five dimensions”,41 which equals 11111. In our sample, 114 (31%) 
patients reported the best possible score at 12 months. While this did not impact our estimation 
of MCID, it does highlight limitation of this instrument and the danger of blind application of a 
threshold on change scores. In our patients, 59% have a baseline score >0.48 (=1 - 0.52), which 
would prevent them from reaching Parker et al’s18 MCID threshold (and for Parker 201117/Asher 
2018
19
 34% are >0.70 (= 1 - 0.30) and for LSOS 13% >0.81 (= 1 - 0.19)). To counteract this 
challenge, the EuroQol Group introduced a revised version, the EQ-5D-5L, with five levels of 
severity for each dimension, allowing patients to be more precise in their health assessment. Its 
validity was first time tested by Herdman et al.
42
 in 2011. Unfortunately, the EQ-5D-5L was not 
available at the start of the LSOS study in the year 2010. 
A limitation of our study was that there is a lack of a “gold” standard measure of HRQOL to 
which the EQ-5D-3L can be compared, although a publication showed that the EQ-5D-3L was 
“the most valid and responsive measure of improvement” for HRQOL (compared to SF-12 and 
Zung Depression Scale) in patients undergoing lumbar fusion surgery.
43
 Further, our patient 
sample included patients with and without degenerative spondylolisthesis − representing a 
typical DLSS population − which might have an influence on the outcome. However, a recent 
study showed no difference in mean EQ-5D after surgery regardless of the presence of a 
preoperative spondylolisthesis.
44
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It is crucial that studies using an MCID value from other publications for their own analyses 
consider the patient population the estimate is based on. For instance, Jansson et al.
45
 who 
investigated patients with LSS who underwent surgery used the calculated MCID from the 
publication of Walters et al.
46
 who compared in eight longitudinal studies with eleven different 
patient groups the MCID (mean value over all studies: 0.074). However, the patient groups were 
quite heterogeneous (the underlying diseases ranged from back pain through irritable bowel 
syndrome to acute myocardial infarction), and therefore, the patients’ chance of improvement 
varies considerably. That might lead to under- or overestimated results. And as discussed above 
future studies should only use the new EQ-5D-5L to reduce potential ceiling effects and hence to 
prevent bias in the outcome.  
When applying these MCID thresholds in future studies, researchers should take care that 
these thresholds are always an average estimate and that individual patients may have greater or 
lower thresholds for perceiving an important change. Given the risk of ceiling effects in EQ-5D-
3L, it might be more appropriate to use a relative measure of improvement, such as the 
percentage of possible improvement (PPI) following Gilmer et al.
47
 and Somerson et al.
48
 in 
addition to the change score. 
 
Conclusion 
In patients with LSS undergoing surgery, we estimated an MCID value for EQ-5D-3L summary 
index of 0.19 with help of the average change anchor-based method, which we find to be the 
most suitable method for assessing patient change scores. 
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 Figure legend 
 
Figure 1: Study flow 
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 Figure 2: Patient reported SSM satisfaction versus EQ-5D-3L change 
There is a positive, albeit weak, relationship (absolute correlation values 0.017 and 0.25) 
between mean SSM satisfaction and mean change in EQ-5D-3L summary index between 12-
month follow-up and baseline. “Somewhat” satisfied patients have a mean SSM satisfaction 
value ≥2 and <2.5, “unsatisfied” patients ≥2.5. In the unsatisfied group: as patient satisfaction 
improved (i.e. became less unsatisfied) changes in EQ-5D-3L became more positive. In the 
somewhat satisfied group, there was no evidence for a positive or negative relationship.. 
Dashed horizontal line: MCID estimation of Parker 2011/Asher 2018 of 0.30; Dotted horizontal 
line: estimation of Parker 2012 of 0.52; R = Pearson correlation coefficient; SSM = Spinal 
Stenosis Measure 
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 Figure 3: Comparison of various MCIDs of EQ-5D-3L to MCID of SSM symptoms and 
function applied to our full patient sample (n=364). 
Solid horizontal line: our MCID estimation of 0.19; Dashed horizontal line: estimation of Parker 
2011/Asher 2018 of 0.30; Dotted horizontal line: estimation of Parker 2012 of 0.52; Solid 
vertical line: MCID estimation of 0.48 (SSM symptoms) and of 0.52 (SSM function), 
respectively; SSM = Spinal Stenosis Measure 
When a patient is above a horizontal line, he reached the respective MCID for EQ-5D-3L. When 
a patient is on the left side of the vertical line, he reached MCID for SSM symptoms or function, 
respectively. 
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Table 1: Patient characteristics at baseline 
Group 
Somewhat 
satisfied 
Unsatisfied p Overall 
n 43 53  96 
Age, years, mean (SD) 74.95 (7.88) 73.83 (8.31) 0.50 74.33 (8.10) 
Female, n (%) 26 (60.5) 32 (60.4) 1.00^ 58 (60.4) 
Social risk*, n (%) 17 (39.5) 18 (34.0) 0.73^ 35 (36.5) 
Education (compulsory school only), n (%) 11 (25.6) 14 (26.4) 1.00^ 25 (26.0) 
BMI, kg/m2, mean (SD) 28.59 (4.66) 27.20 (4.81) 0.16 27.82 (4.77) 
Smoker, n (%) 7 (16.3) 10 (18.9) 0.95^ 17 (17.7) 
CIRS, mean (SD) 10.58 (3.36) 10.75 (4.57) 0.84 10.68 (4.06) 
Duration of symptoms >6 months, n (%) 31 (72.1) 42 (79.2) 0.57^ 73 (76.0) 
Spondylolisthesis+ on operated level, n (%) 28 (65.1) 34 (64.2) 1.00^ 62 (64.6) 
EQ-5D-3L summary index, mean (SD) 0.45 (0.28) 0.35 (0.31) 0.10 0.40 (0.30) 
Days between initial operation and 12-
month follow-up, mean (SD) 
340.7 (33.0) 341.7 (39.1) 0.90 341.2 (36.3) 
Days between baseline and 12-month 
follow-up, mean (SD) 
367.0 (8.1) 368.9 (10.8) 0.34 368.1 (9.7) 
All p-values are from a Welch two-sided t-test unless otherwise noted. 
CIRS, Cumulative Illness Rating Scale 
+ Meyerding listhesis grade ≥1 
* Living alone, or single/divorced/widowed and living in a nursing/residential home. 
^ p-value from a chi-squared test. 
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